SKS Ocular Overview

  • Founded
  • 2010
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Financing Rounds
  • 1

SKS Ocular General Information

Description

Operator of a biopharmaceutical company. The company is developing a sustained-release technology platform to develop drug formulations for ocular disease. The platform employs micro fabrication techniques to create nano and microparticle drug formulations that can provide sustained and predictable release of a therapeutic drug over a 3 - 6 month period. The company has four active pipelines under way in glaucoma, steroid-induced glaucoma, allergic conjunctivitis and protein delivery.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Primary Office
  • 5871 Oberlin Drive
  • Suite 150
  • San Diego, CA 92121
  • United States
+1 (858) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

SKS Ocular Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore SKS Ocular‘s full profile, request access.

Request a free trial

SKS Ocular Executive Team (4)

Name Title Board Seat Contact Info
Peter Kaiser MD Co-Founder
Jason Slakter MD President, Co-Founder & Chief Executive Officer
Glenn Stoller MD Chief Scientific Officer & Co-Founder
Daniel Dubin MD Advisor
To view SKS Ocular’s complete executive team members history, request access »